格帕沙星（GSK2140944）及其他抗菌药物对人型支原体和脲原体的活性。
Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.
机构信息
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
出版信息
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01064-17. Print 2017 Oct.
Abstract
Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates of , , , , and in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MICs (μg/ml) were 0.125 (), 0.032 (), 2 (), and 8 ( species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.
摘要
革巴地辛，一种新型的三氮杂吖庚因拓扑异构酶 II 抑制剂，与左氧氟沙星、莫西沙星、阿奇霉素或克林霉素和四环素相比，对 85 株标准株和临床分离株进行了测试，包括 、 、 、 和 。革巴地辛 MIC（μg/ml）分别为 0.125（ ）、0.032（ ）、2（ ）和 8（ ）。革巴地辛在测试的菌株中对氟喹诺酮类、四环素类或大环内酯类药物的耐药性没有影响。革巴地辛值得进一步研究，以治疗这些病原体引起的感染。
相似文献
1
Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.格帕沙星（GSK2140944）及其他抗菌药物对人型支原体和脲原体的活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01064-17. Print 2017 Oct.
2
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.苯并喹喔啉氟喹诺酮类左氧氟沙星（WCK 771）和其他抗菌药物对人类支原体和脲原体的活性，包括具有明确耐药机制的分离株。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
3
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物DC-159a与其他抗菌药物对人支原体和脲原体的体外活性比较
Antimicrob Agents Chemother. 2008 Oct;52(10):3776-8. doi: 10.1128/AAC.00849-08. Epub 2008 Jul 28.
4
In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.奥马环素（PTK 0796）及其他抗菌药物对人型支原体和脲原体的体外活性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7502-7504. doi: 10.1128/AAC.01734-16. Print 2016 Dec.
5
Evaluation of commercial, customized microdilution plates for , , and antimicrobial susceptibility testing and determination of antimicrobial resistance prevalence in France.评估商业定制微量稀释板在法国进行抗菌药物敏感性测试和确定抗菌药物耐药率的应用。
J Clin Microbiol. 2024 Jul 16;62(7):e0022624. doi: 10.1128/jcm.00226-24. Epub 2024 Jun 4.
6
In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years.20 多年来德国分离的人型支原体和脲原体对四环素类、大环内酯类、氟喹诺酮类和克林霉素的体外活性。
Clin Microbiol Infect. 2010 Nov;16(11):1649-55. doi: 10.1111/j.1469-0691.2009.03155.x.
7
Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.依拉环素及其他抗菌药物对人型支原体和脲原体的活性
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00698-20.
8
Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.人型支原体、肺炎支原体和解脲脲原体对GAR-936、达福普汀、地红霉素、依维霉素、加替沙星、利奈唑胺、莫西沙星、奎奴普丁-达福普汀和泰利霉素的敏感性与其对参考大环内酯类、四环素类和喹诺酮类药物的敏感性比较。
Antimicrob Agents Chemother. 2001 Sep;45(9):2604-8. doi: 10.1128/AAC.45.9.2604-2608.2001.
9
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.人型支原体和脲原体对新型研究性酮内酯类药物CEM-101的体外敏感性比较
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
10
Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years.7 年来在意大利布雷西亚分离的人型支原体和脲原体的发生率和抗生素敏感性。
J Infect Chemother. 2013 Aug;19(4):621-7. doi: 10.1007/s10156-012-0527-z. Epub 2012 Nov 29.
引用本文的文献
1
Antimicrobial susceptibility and genetic mechanisms of resistance of isolates in North America between 2012 and 2023.2012年至2023年北美分离株的抗菌药物敏感性及耐药基因机制
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0186824. doi: 10.1128/aac.01868-24. Epub 2025 May 5.
2
Antibiotics in the clinical pipeline as of December 2022.截至 2022 年 12 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
3
Latest Advances in Laboratory Detection of Mycoplasma genitalium.生殖支原体的实验室检测最新进展
J Clin Microbiol. 2023 Mar 23;61(3):e0079021. doi: 10.1128/jcm.00790-21. Epub 2023 Jan 4.
4
Recent advances in understanding and combatting .在理解和对抗方面的最新进展。 （原句不完整，此为按现有内容翻译）
Fac Rev. 2020 Oct 30;9:3. doi: 10.12703/b/9-3. eCollection 2020.
5
Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.优化性传播感染治疗：监测、药代动力学和药效学、治疗策略和分子耐药性预测。
Lancet Infect Dis. 2020 Aug;20(8):e181-e191. doi: 10.1016/S1473-3099(20)30171-7. Epub 2020 Jun 19.
6
activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible .第一类三氮杂萘并嘧啶 gepotidacin 单独及与多西环素联合用于治疗耐药和敏感.
Emerg Microbes Infect. 2020 Dec;9(1):1388-1392. doi: 10.1080/22221751.2020.1775498.
7
Antibiotics in the clinical pipeline in October 2019.2019 年 10 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10.
8
Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs).两 decade 成功的 SAR 为基础的 novel 细菌拓扑异构酶抑制剂（NBTIs）的故事。
J Med Chem. 2020 Jun 11;63(11):5664-5674. doi: 10.1021/acs.jmedchem.9b01738. Epub 2020 Feb 17.
本文引用的文献
1
Gepotidacin (GSK2140944) Activity against Gram-Positive and Gram-Negative Bacteria.格帕沙星（GSK2140944）对革兰氏阳性菌和革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00468-17. Print 2017 Jul.
2
In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.来法莫林及其他抗菌药物对来自美国、欧洲和中国的大环内酯类敏感及大环内酯类耐药肺炎支原体的体外活性
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.02008-16. Print 2017 Feb.
3
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.新型三氮杂苊烯细菌拓扑异构酶抑制剂格波达辛对多种细菌病原体的体外活性
Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.
4
Macrolide-Resistant Mycoplasma pneumoniae, United States.美国耐大环内酯类肺炎支原体
Emerg Infect Dis. 2015 Aug;21(8):1470-2. doi: 10.3201/eid2108.150273.
5
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.AZD0914对人支原体和脲原体的体外抗菌活性。
Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.
6
Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.解脲支原体中氟喹诺酮类和大环内酯类耐药相关的突变。
J Clin Microbiol. 2013 Jul;51(7):2245-9. doi: 10.1128/JCM.00495-13. Epub 2013 May 8.
7
Mycoplasma genitalium: from Chrysalis to multicolored butterfly.生殖道支原体：从蛹到五彩蝴蝶。
Clin Microbiol Rev. 2011 Jul;24(3):498-514. doi: 10.1128/CMR.00006-11.
8
Type IIA topoisomerase inhibition by a new class of antibacterial agents.新型抗菌药物对 IIA 拓扑异构酶的抑制作用。
Nature. 2010 Aug 19;466(7309):935-40. doi: 10.1038/nature09197. Epub 2010 Aug 4.
9
Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance.临床分离株中出现与氟喹诺酮耐药相关的 ParC 改变的生殖支原体。
Int J Antimicrob Agents. 2010 Sep;36(3):255-8. doi: 10.1016/j.ijantimicag.2010.05.011. Epub 2010 Jun 30.
10
Azithromycin failure in Mycoplasma genitalium urethritis.阿奇霉素治疗解脲脲原体尿道炎失败
Emerg Infect Dis. 2006 Jul;12(7):1149-52. doi: 10.3201/eid1207.051558.
Zotero 插件